GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jiangsu Hengrui Pharmaceuticals Co Ltd (SHSE:600276) » Definitions » Piotroski F-Score

Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Piotroski F-Score : 8 (As of Apr. 26, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Jiangsu Hengrui Pharmaceuticals Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 8, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jiangsu Hengrui Pharmaceuticals Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score or its related term are showing as below:

SHSE:600276' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 9
Current: 8

During the past 13 years, the highest Piotroski F-Score of Jiangsu Hengrui Pharmaceuticals Co was 9. The lowest was 2. And the median was 6.


Jiangsu Hengrui Pharmaceuticals Co Piotroski F-Score Historical Data

The historical data trend for Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jiangsu Hengrui Pharmaceuticals Co Piotroski F-Score Chart

Jiangsu Hengrui Pharmaceuticals Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.00 4.00 4.00 3.00 8.00

Jiangsu Hengrui Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 6.00 8.00 8.00 8.00

Competitive Comparison of Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score

For the Drug Manufacturers - General subindustry, Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was 1069.158 + 1165.514 + 828.657 + 1368.929 = ¥4,432 Mil.
Cash Flow from Operations was 2661.379 + 1433.523 + 3334.794 + 1254.599 = ¥8,684 Mil.
Revenue was 5676.059 + 5845.253 + 5806.153 + 5997.534 = ¥23,325 Mil.
Gross Profit was 4766.204 + 4957.071 + 4938.459 + 5054.685 = ¥19,716 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(42293.83 + 41961.333 + 42871.391 + 43784.507 + 46340.001) / 5 = ¥43450.2124 Mil.
Total Assets at the begining of this year (Mar23) was ¥42,294 Mil.
Long-Term Debt & Capital Lease Obligation was ¥78 Mil.
Total Current Assets was ¥33,712 Mil.
Total Current Liabilities was ¥3,698 Mil.
Net Income was 882.383 + 1054.058 + 732.985 + 1239.107 = ¥3,909 Mil.

Revenue was 4749.503 + 5717.264 + 5329.965 + 5492.32 = ¥21,289 Mil.
Gross Profit was 3916.872 + 4736.442 + 4512.074 + 4632.803 = ¥17,798 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(39817.549 + 40745.926 + 40175.042 + 42370.876 + 42293.83) / 5 = ¥41080.6446 Mil.
Total Assets at the begining of last year (Mar22) was ¥39,818 Mil.
Long-Term Debt & Capital Lease Obligation was ¥84 Mil.
Total Current Assets was ¥30,650 Mil.
Total Current Liabilities was ¥2,537 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jiangsu Hengrui Pharmaceuticals Co's current Net Income (TTM) was 4,432. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Jiangsu Hengrui Pharmaceuticals Co's current Cash Flow from Operations (TTM) was 8,684. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=4432.258/42293.83
=0.1047968

ROA (Last Year)=Net Income/Total Assets (Mar22)
=3908.533/39817.549
=0.09816106

Jiangsu Hengrui Pharmaceuticals Co's return on assets of this year was 0.1047968. Jiangsu Hengrui Pharmaceuticals Co's return on assets of last year was 0.09816106. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Jiangsu Hengrui Pharmaceuticals Co's current Net Income (TTM) was 4,432. Jiangsu Hengrui Pharmaceuticals Co's current Cash Flow from Operations (TTM) was 8,684. ==> 8,684 > 4,432 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=78.398/43450.2124
=0.00180432

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=83.914/41080.6446
=0.00204267

Jiangsu Hengrui Pharmaceuticals Co's gearing of this year was 0.00180432. Jiangsu Hengrui Pharmaceuticals Co's gearing of last year was 0.00204267. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=33712.252/3698.072
=9.11616972

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=30650.444/2536.713
=12.08274014

Jiangsu Hengrui Pharmaceuticals Co's current ratio of this year was 9.11616972. Jiangsu Hengrui Pharmaceuticals Co's current ratio of last year was 12.08274014. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Jiangsu Hengrui Pharmaceuticals Co's number of shares in issue this year was 6518.711. Jiangsu Hengrui Pharmaceuticals Co's number of shares in issue last year was 6521.618. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=19716.419/23324.999
=0.84529131

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=17798.191/21289.052
=0.83602553

Jiangsu Hengrui Pharmaceuticals Co's gross margin of this year was 0.84529131. Jiangsu Hengrui Pharmaceuticals Co's gross margin of last year was 0.83602553. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=23324.999/42293.83
=0.55149886

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=21289.052/39817.549
=0.53466505

Jiangsu Hengrui Pharmaceuticals Co's asset turnover of this year was 0.55149886. Jiangsu Hengrui Pharmaceuticals Co's asset turnover of last year was 0.53466505. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+0+1+1+1
=8

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Jiangsu Hengrui Pharmaceuticals Co has an F-score of 8. It is a good or high score, which usually indicates a very healthy situation.

Jiangsu Hengrui Pharmaceuticals Co  (SHSE:600276) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Jiangsu Hengrui Pharmaceuticals Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Jiangsu Hengrui Pharmaceuticals Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Business Description

Traded in Other Exchanges
N/A
Address
No. 38, Huanghe Road, Economic, Economic and Technological Development Zone, Jiangsu Province, Lianyugang, CHN, 222047
Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications. It specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system.

Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Headlines

No Headlines